[Inflammatory Muscle Pain: Polymyalgia Rheumatica with or without Large Vessel Vasculitis].
Polymyalgia rheumatica mit und ohne Großgefäßvaskulitis.
Aged
Antibodies, Monoclonal, Humanized
/ therapeutic use
Blindness
/ diagnosis
Diagnosis, Differential
Fatigue
/ etiology
Female
Giant Cell Arteritis
/ diagnosis
Humans
Methotrexate
/ therapeutic use
Polymyalgia Rheumatica
/ diagnosis
Prednisolone
/ therapeutic use
Stroke
/ etiology
Ultrasonography
Vasculitis
/ diagnosis
Journal
Deutsche medizinische Wochenschrift (1946)
ISSN: 1439-4413
Titre abrégé: Dtsch Med Wochenschr
Pays: Germany
ID NLM: 0006723
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
entrez:
3
7
2020
pubmed:
3
7
2020
medline:
2
2
2021
Statut:
ppublish
Résumé
Polymyalgia rheumatica (PMR) is characterized by rapidly evolving shoulder and pelvic girdle pain with fatigue, weight loss, night sweats and elevated CRP and ESR. Giant cell arteritis (GCA) can occur in PMR and vice versa. Headache and scalp tenderness are typical for GCA. GCA may be complicated by visual loss or by strokes.Imaging, particularly ultrasound, is helpful for distinguishing PMR from similar conditions such as shoulder osteoarthritis, rheumatoid arthritis and chondrocalcinosis. Subdeltoid bursitis, biceps tenosynovitis and hip joint effusions are common in PMR. The diagnosis of GCA needs to be either confirmed by imaging or by histology. Ultrasound is the imaging method of choice provided that expertise and adequate equipment are available. Inflamed arteries exhibit a concentric wall thickening. Patients with extracranial GCA are younger, more often female. Vasculitis commonly involves the aorta, subclavian arteries, axillary arteries and other arteries. The diagnosis of extracranial GCA may be confirmed by ultrasound, CT, MRI or PET.Prednisolone with a starting dose of 15-25 mg/d for PMR and of 40-60 mg/d for GCA results in rapid improvement of symptoms. Fast-track clinics provide clinical and ultrasound examinations by experts within 24 hours. Their introduction led to a decrease of visual loss in GCA. The prednisolone dose can be discontinued within 1 year in about 50 % of GCA patients. Additional treatment with tocilizumab allows to reduce flares and decrease glucocorticoid doses. Tocilizumab is particularly useful in patients with relapses and with increased risk of glucocorticoid side effects.
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Prednisolone
9PHQ9Y1OLM
tocilizumab
I031V2H011
Methotrexate
YL5FZ2Y5U1
Types de publication
Case Reports
Journal Article
Review
Langues
ger
Sous-ensembles de citation
IM
Pagination
895-902Informations de copyright
© Georg Thieme Verlag KG Stuttgart · New York.
Déclaration de conflit d'intérêts
Honorare für Vorträge: Chugai, Medac, Novartis, Roche, SanofiHororare für Beratertätigkeit: Chugai, Novartis, Roche, SanofiPrinicple Investigator von Studien: Novartis, SanofiArbeitgeber: Immanuel Krankenhaus Berlin, Rheumaklinik Berlin-Buch, Leitender OberarztMitgliedschaften:EULAR: Coopted Member of Standing Committee on Musculoskeletal ImagingAmerican College of Rheumatology (ACR)Deutsche Gesellschaft für Rheumatologie (DGRh)Deutsche Gesellschaft für Ultraschall in der Medizin (DEGUM): Stufe 3 BewegungsorganeBerufsverband Deutscher Internisten (BDI)Deutsche Rheumaliga